Rationale and design of a prospective study of the efficacy of a remote monitoring system used in implantable cardioverter defibrillator follow-up: the Lumos-T Reduces Routine Office Device Follow-Up Study (TRUST) study
- PMID: 18035071
- DOI: 10.1016/j.ahj.2007.07.051
Rationale and design of a prospective study of the efficacy of a remote monitoring system used in implantable cardioverter defibrillator follow-up: the Lumos-T Reduces Routine Office Device Follow-Up Study (TRUST) study
Abstract
Increased implantable cardioverter defibrillator (ICD) implant volumes (and product advisories/recalls) pose management challenges. Most device interrogations at 3- to 6-month routine follow-up visits are "nonactionable," that is, require no clinically significant reprogramming, lead revision, or initiation or up-titration of antiarrhythmic medications. Conversely, implanted devices collect important diagnostic data (eg, atrial fibrillation onset, system integrity) that remain concealed between device interrogations. Remote monitoring may resolve some of these challenges, but has not been studied in a large-scale clinical trial. Home Monitoring (HM) uses automatic (without patient intervention) data and electrogram transmissions with rapid (<24 hours) event notification of significant (including silent) events. The Lumos-T Reduces Routine Office Device Follow-Up Study (TRUST) is a multicenter, prospective, randomized study enrolling 1000 ICD patients designed to test whether HM can safely reduce the number of scheduled nonactionable office device interrogations by 50% and provide early detection and notification of cardiac and/or device problems. After enrollment, TRUST patients are randomized 2:1 to either HM or to control (ie, HM off) arms and are seen for an in-office follow-up 3 months postimplant. At subsequent 3-month intervals, control patients have conventional office visits, whereas in HM, patient data are remotely retrieved and evaluated. In HM patients, early notification may automatically occur between periodic checks for compromised system integrity (battery, lead parameters, high-voltage circuitry) or arrhythmia occurrence (eg, atrial fibrillation, ventricular arrhythmia). All study patients will have a final office visit 15 months after implant. The results of TRUST may confirm the role of remote monitoring as an intensive surveillance mechanism for device management.
Similar articles
-
Automatic remote monitoring of implantable cardioverter-defibrillator lead and generator performance: the Lumos-T Safely RedUceS RouTine Office Device Follow-Up (TRUST) trial.Circ Arrhythm Electrophysiol. 2010 Oct;3(5):428-36. doi: 10.1161/CIRCEP.110.951962. Epub 2010 Aug 17. Circ Arrhythm Electrophysiol. 2010. PMID: 20716717 Clinical Trial.
-
Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial.Circulation. 2010 Jul 27;122(4):325-32. doi: 10.1161/CIRCULATIONAHA.110.937409. Epub 2010 Jul 12. Circulation. 2010. PMID: 20625110 Clinical Trial.
-
Potential role of remote monitoring for scheduled and unscheduled evaluations of patients with an implantable defibrillator.Europace. 2008 Mar;10(3):351-7. doi: 10.1093/europace/eun010. Epub 2008 Feb 1. Europace. 2008. PMID: 18245771
-
[The place of telemedicine in rhythmology and cardiac pacing].Arch Mal Coeur Vaiss. 2004 Nov;97(11):1160-4. Arch Mal Coeur Vaiss. 2004. PMID: 15609921 Review. French.
-
Should recent defibrillator and lead advisories affect decisions to refer patients for implantable cardioverter-defibrillator therapy?Curr Opin Cardiol. 2010 Jan;25(1):23-8. doi: 10.1097/HCO.0b013e328333d375. Curr Opin Cardiol. 2010. PMID: 19907318 Review.
Cited by
-
Telecardiology and its outcome among patients with implantable cardiac devices during COVID-19 pandemic.ARYA Atheroscler. 2021 Nov;17(6):1-6. doi: 10.22122/arya.v17i0.2354. ARYA Atheroscler. 2021. PMID: 35685449 Free PMC article.
-
[Telemedicine in pacemaker therapy and follow-up].Herzschrittmacherther Elektrophysiol. 2009 Dec;20(4):164-72. doi: 10.1007/s00399-009-0058-1. Herzschrittmacherther Elektrophysiol. 2009. PMID: 19937330 German.
-
Alert-driven vs scheduled remote monitoring of implantable cardiac defibrillators: A cost-consequence analysis from the TRUST trial.Heart Rhythm. 2023 Mar;20(3):440-447. doi: 10.1016/j.hrthm.2022.12.003. Epub 2022 Dec 8. Heart Rhythm. 2023. PMID: 36503177 Free PMC article. Clinical Trial.
-
Strategic choices to reduce implantable cardioverter-defibrillator-related morbidity.Nat Rev Cardiol. 2010 Jul;7(7):376-83. doi: 10.1038/nrcardio.2010.50. Epub 2010 Apr 20. Nat Rev Cardiol. 2010. PMID: 20404852 Review.
-
Telemedicine and cardiac implants: what is the benefit?Eur Heart J. 2013 Jul;34(25):1885-95. doi: 10.1093/eurheartj/ehs388. Epub 2012 Dec 4. Eur Heart J. 2013. PMID: 23211231 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical